Statin Therapy and Saphenous Vein Graft Disease After Coronary Bypass Surgery: Analysis From the CASCADE Randomized Trial

被引:72
|
作者
Kulik, Alexander
Voisine, Pierre
Mathieu, Patrick
Masters, Roy G.
Mesana, Thierry G.
Le May, Michel R.
Ruel, Marc [1 ]
机构
[1] Univ Ottawa, Inst Heart, Div Cardiac Surg, Ottawa, ON K1Y 4W7, Canada
关键词
MUSCLE-CELL-PROLIFERATION; LIPOPROTEIN CHOLESTEROL LEVELS; LOW-DOSE ANTICOAGULATION; TREATMENT PANEL-III; ARTERY-DISEASE; SECONDARY PREVENTION; MYOCARDIAL-INFARCTION; OUTCOMES; ATORVASTATIN; SIMVASTATIN;
D O I
10.1016/j.athoracsur.2011.04.107
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Current guidelines recommend statin therapy after coronary artery bypass grafting (CABG) to attain low-density lipoprotein (LDL) levels less than 100 mg/dL. Whether achieving LDL levels less than 70 mg/dL improves postoperative graft patency remains unknown. Methods. The CASCADE (Clopidogrel after Surgery for Coronary Artery Disease) trial was a randomized study that evaluated the addition of clopidogrel to aspirin on the development of saphenous vein graft disease after CABG. Patients received the standard of care regarding postoperative statin therapy with targeted LDL levels less than 100 mg/dL. Twelve months postoperatively, patients returned for a coronary angiogram and saphenous vein graft (SVG) intravascular ultrasonogram. In this post hoc analysis, the impact of statin therapy on graft patency and vein graft intimal hyperplasia was assessed. Results. LDL levels significantly declined over the period of the trial (p = 0.002). Twelve months postoperatively, 58.4% patients achieved LDL levels less than 70 mg/dL. Twelve-month graft patency was higher for patients with LDL levels less than 100 mg/dL (96.5%) compared with patients with LDL levels > 100 mg/dL (83.3%, p = 0.03), even after adjustment in multivariate analysis (odds ratio [OR], 5.2; 95% confidence interval [CI], 1.3-21.6; p = 0.02). However, no improvement in graft patency was noted with further LDL reduction to less than 70 mg/dL (p = 1.00). Consistent statin use throughout the trial period was independently associated with less vein graft intimal hyperplasia documented by intravascular ultrasound at 12 months (p = 0.04). Conclusions. Statin therapy to achieve LDL levels less than 100 mg/dL was independently associated with improved graft patency in the CASCADE trial. Randomized clinical trials are warranted to prospectively evaluate postoperative LDL reduction to less than 70 mg/dL and its impact on graft patency after CABG. (Ann Thorac Surg 2011;92:1284-91) (C) 2011 by The Society of Thoracic Surgeons
引用
收藏
页码:1284 / 1290
页数:7
相关论文
共 50 条
  • [1] Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial
    Kulik, Alexander
    Abreu, Amy M.
    Boronat, Viviana
    Ruel, Marc
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 157 (01) : 151 - +
  • [2] Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial
    Jerzewski, Katie
    Ruel, Marc
    Voisine, Pierre
    Le May, Michel R.
    Kulik, Alexander
    JOURNAL OF CARDIOTHORACIC SURGERY, 2013, 8
  • [3] Effects of Aggressive Statin Therapy on Patients With Coronary Saphenous Vein Bypass Grafts: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials
    Kang, Sheng
    Liu, Yong
    Liu, Xue-bo
    CLINICAL THERAPEUTICS, 2013, 35 (08) : 1125 - 1136
  • [4] Symptomatic late saphenous vein graft failure in coronary artery bypass surgery
    Janiec, Mikael
    Dimberg, Axel
    Lindblom, Rickard P. F.
    INTERDISCIPLINARY CARDIOVASCULAR AND THORACIC SURGERY, 2023, 36 (04):
  • [5] Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery Pathophysiology, Management, and Future Directions
    Harskamp, Ralf E.
    Lopes, Renato D.
    Baisden, Clinton E.
    de Winter, Robbert J.
    Alexander, John H.
    ANNALS OF SURGERY, 2013, 257 (05) : 824 - 833
  • [6] Perioperative Statin Therapy Is Associated With a Significant and Dose-Dependent Reduction of Adverse Cardiovascular Outcomes After Coronary Artery Bypass Graft Surgery
    Ouattara, Alexandre
    Benhaoua, Hamina
    Le Manach, Yannick
    Mabrouk-Zerguini, Nejma
    Itani, Omar
    Osman, Amer
    Landi, Marc
    Riou, Bruno
    Coriat, Pierre
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2009, 23 (05) : 633 - 638
  • [7] The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial
    Eisen, Alon
    Cannon, Christopher P.
    Blazing, Michael A.
    Bohula, Erin A.
    Park, Jeong-Gun
    Murphy, Sabina A.
    White, Jennifer A.
    Giugliano, Robert P.
    Braunwald, Eugene
    EUROPEAN HEART JOURNAL, 2016, 37 (48) : 3576 - 3584
  • [8] Ticagrelor versus aspirin and vein graft patency after coronary bypass: A randomized trial
    Kulik, Alexander
    Abreu, Amy M.
    Boronat, Viviana
    Kouchoukos, Nicholas T.
    Ruel, Marc
    JOURNAL OF CARDIAC SURGERY, 2022, 37 (03) : 563 - 570
  • [9] Endoscopic versus direct vision for saphenous vein graft harvesting in coronary artery bypass surgery
    Ad, N.
    Henry, L.
    Hunt, S.
    Holmes, S. D.
    Burton, N.
    Massimiano, P.
    Rhee, J.
    Rongione, A.
    Speir, A.
    Collazo, L.
    JOURNAL OF CARDIOVASCULAR SURGERY, 2011, 52 (05) : 739 - 748
  • [10] CHA2DS2-Vasc score and saphenous vein graft disease in patients with coronary artery bypass graft surgery
    Yarlioglues, Mikail
    Oksuz, Fatih
    Yalcinkaya, Damla
    Duran, Mustafa
    Murat, Sani Namik
    CORONARY ARTERY DISEASE, 2020, 31 (03) : 243 - 247